ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
Background and purpose Nelfinavir can enhance intrinsic radiosensitivity, reduce hypoxia and improve vascularity. We conducted a phase II trial combining nelfinavir with chemoradiotherapy (CRT) for locally advanced inoperable pancreatic cancer (LAPC). Materials and methods Radiotherapy (50.4 Gy/28...
Автори: | Wilson, J, Fokas, E, Dutton, S, Hawkins, M, al., E |
---|---|
Формат: | Journal article |
Опубліковано: |
Elsevier
2016
|
Схожі ресурси
Схожі ресурси
-
ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–mechanism and clinical outcomes
за авторством: Wilson, J, та інші
Опубліковано: (2017) -
A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
за авторством: Brunner, T, та інші
Опубліковано: (2008) -
A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
за авторством: Brunner, T, та інші
Опубліковано: (2008) -
Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
за авторством: Brunner, T, та інші
Опубліковано: (2008) -
HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment
за авторством: Unaí Tupinambás, та інші